Annexin-1 Downregulation Is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Wang, D.; Zhang, H.; Zheng, Fang; Yu, Guanzhen

doi:10.1159/000320237

Cited by 15 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the trend of ANXA1 up-regulation in tumors was not significant in colorectal and hepatocellular adenocarcinoma, which may be due to limited sample numbers. Interestingly, loss of ANXA1 expression has also been described in some tumors, for example, in breast cancer, cholangiocarcinoma, and gastric cancer [5,21,23]. In present study, however, we observed a significant loss of ANXA1 expression in cholangiocarcinoma and gastric cancer.…”

Section: Discussioncontrasting

confidence: 62%

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Gao

Chen

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

BackgroundAnnexin-1 contributes to the pathological consequence and sequelae of most serious human diseases including cardiovascular disease and cancer. Although diverse roles in carcinogenesis have been postulated, its role in human gastrointestinal cancers still remains controversial.MethodsThe mRNA and protein expression profiles of ANXA1 were studied in human esophageal, gastric, pancreatic, colorectal, liver, and bile duct cancers using Real-Time PCR, western blotting, and immunohistochemistry. Gain/loss-of-function by pcDNA3.1-ANXA1 and ANXA1-shRNA was performed in gastric cancer cells.ResultsANXA1 was widely expressed in adult gastrointestinal tissue. All methods showed that ANXA1 was down-regulated in esophageal, gastric, and bile duct cancers, but up-regulated in pancreatic cancer. Forced ANXA1 expression in gastric cancer cells leads to cell growth inhibition and concomitantly modulates COX-2 expression. We confirm loss of ANXA1 and overexpression of COX-2 in clinical gastric cancer, suggesting that the anti-proliferative function of ANXA1 against COX-2 production might be lost.ConclusionsANXA1 expression is “tumor-specific” and might play a multifaceted role in cancer development and progression. ANXA1 was widely expressed in normal gastrointestinal epithelium, suggesting its role in the maintenance of cellular boundaries. Furthermore, ANXA1 regulates GC cell viability via the COX-2 pathway.

show abstract

Section: Discussioncontrasting

confidence: 62%

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Gao

Chen

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Possible reasons for this discrepancy are the limited number of subjects in the cohort and the fact that this cohort involved a number of patients with HC with advanced-stage disease. A number of studies have introduced biological markers into the Cox regression model, including amino acid transporter A1, proline-rich protein 11, pyruvate kinase PKM and Annexin A1 (12,13,(22)(23)(24). The survival analysis from the present study showed that high FOXK1 expression in tumors was associated with shorter PFS and worse outcome.…”

Section: Discussionmentioning

confidence: 56%

FOXK1 plays an oncogenic role in the progression of hilar cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

Hilar cholangiocarcinoma (HC) has a poor outcome in terms of survival. Forkhead box K1 (FOXK1) dysregulation is critical in solid tumors, which serves a pivotal role in the biological characteristics, such as invasion and migration, but its expression and functions in HC are unclear. The present study investigated the clinical significance and biological functions of FOXK1 in HC. Tumor microarrays and immunohistochemistry were used to evaluate FOXK1 in HC and its expression was modulated to determine its effects on chemoresistance and tumorigenesis. FOXK1 was highly expressed in HC and cell lines, which was associated with tumor invasion, regional lymph node metastasis, tumor recurrence and poor prognosis. Silencing FOXK1 in HC cells inhibited invasion and migration, upregulated E-cadherin, and downregulated vimentin, matrix metallopeptidase 9 and Twist in HC cells. Sensitivity to 5-fluorouracil and cisplatin was increased, and glutathione S-transferase π, multidrug resistance mutation 1 and P-glycoprotein expression levels were downregulated in RBE cells in vitro following FOXK1 knockdown. These results indicated that FOXK1 plays an oncogenic role in HC progression and can serve as a novel therapeutic target for HC.

show abstract

“…Annexin A1 may have important regulatory roles in tumor development and progression, but these findings are highly controversial, and the mechanism of its involvement in carcinogenesis and tumor progression is unclear. The downregulation of annexin A1 expression in certain cancers (8–28) and the upregulation in other cancer types support this involvement (19, 28–45). Table I summarizes the studies performed on clinical cancer cells and tissues with decreased annexin A1 expression.…”

Section: Expression Pattern Of Annexin A1 In Tumorsmentioning

confidence: 80%

Annexin A1 in Malignant Tumors: Current Opinions and Controversies

2014

View full text Add to dashboard Cite

Annexin A1 is a 37 kDa calcium and phospholipid-binding protein that participates in several biological processes, such as inflammatory reactions, modulation of cell proliferation, regulation of cell death signaling, apoptosis, and, most importantly, tumor formation and development. Although annexin A1 has been implicated in the biology of various tumors, the findings are highly controversial and information regarding the underlying mechanism remains limited. Moreover, the mechanism by which annexin A1 participates in carcinogenesis and tumor progression is rather unclear. In the current study, we review the important biological functions of annexin A1 in different tumors. This work indicates that annexin A1 is a possible target for novel therapeutic intervention and that it is a potential biomarker for tumor diagnosis and screening.

show abstract

Annexin-1 Downregulation Is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Cited by 15 publications

References 60 publications

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers

FOXK1 plays an oncogenic role in the progression of hilar cholangiocarcinoma

Annexin A1 in Malignant Tumors: Current Opinions and Controversies

Contact Info

Product

Resources

About